HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trump Signs US Appropriations-COVID Relief Bill With Cosmetics, Cannabis, Dietary Provisions

Executive Summary

The Consolidated Appropriations Act, H.R. 133, includes $900bn in unemployment relief to COVID victims as well as regular federal appropriations to avoid a looming government shutdown. US FDA provisions include cosmetics and nutrition industry mentions.

You may also be interested in...



Requiring Infant Formula, Medical Food Shortage Updates Included In US FDA Budget Request

FDA’s justification report published with Biden administration’s FY2022 federal budget request includes $1.194bn for agency’s food programs, which include its oversight of supplement industry, up from $1.11bn in FY2021 appropriation.

CBD Class-Action Litigants Watching For Retroactive Effects In US FDA’s Awaited Rulemaking

Even in the “highly unlikely event” that the FDA does make CBD supplements legal, it will not do so retroactively, according to plaintiffs against CV Sciences in California’s Central District. However, the federal court, which also is hearing a similar case against competitor Charlotte’s Web, is not convinced.

NGOs To Assert COVID-Unsafe Cosmetic Ingredients In Next US Legislative Reform Push

The Campaign for Safe Cosmetics, powered by Breast Cancer Prevention Partners and the Environmental Working Group, intends to present the 117th Congress with links between cosmetic ingredients and increased COVID susceptibility as part of its push for tighter cosmetics industry oversight.

Related Content

Topics

UsernamePublicRestriction

Register

RS150845

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel